Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm Therapeutics ( KPTI ) financial results report revenues from a strong launch of its first approved product. Indeed, the firm’s third-quarter 2019 financial results...

November 6, 2019

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the...

June 4, 2019

Can this small firm defeat multiple-drug resistant infections and life-threatening fungal infections?

Cidara Therapeutics (CDTX) , a biotechnology company developing novel anti-infective products, including immunotherapies, announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), awarded it and Rutgers University a five-year, $5.5 million partnership grant. The grant...

May 21, 2018

Exelixis and Daiichi Sankyo: Preventing and Treating Diabetic Nephropathy

Exelixis and Daiichi Sankyo Partner to Prevent and Treat Diabetic Nephropathy Exelixis ( EXEL ) and Daiichi Sankyo ( DSNKY ) reported positive results from a phase 3 pivotal trial of esaxerenone , a product of the companies’ prior research...

November 8, 2019

Rhythm Pharmaceuticals: Treating Obesity Prevents and Reverses Intractable Life-Threatening Diseases

Based in Boston, MA, Rhythm Pharmaceuticals (RYTM) – is a company focused on discovering and developing treatments for rare genetic disorders of obesity. It is currently evaluating the efficacy and safety of setmelanotide , its first-in-class melanocortin-4 receptor (MC4R) agonist,...

May 16, 2018

On CRISPR Therapeutics’ news

CRISPR Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) announced that The U.S. Food and Drug Administration (FDA) has placed a clinical hold on the Investigational New Drug Application (IND) for CTX001 for the treatment of sickle cell disease pending the resolution of certain questions...

May 31, 2018

The FDA accepted Exelixis’ supplemental new drug application of Cabometyx® for previously treated advanced Hepatocellular Carcinoma. The FDA approved Imdexxy developed by TherapeuticsMD for moderate to severe Dyspareunia

The U.S. Food and Drug Administration (FDA) has accepted for filing Exelixis’ (EXEL) supplemental New Drug Application (sNDA) for Cabometyx® (cabozantinib) tablets for patients with previously treated advanced hepatocellular carcinoma (HCC). The FDA has determined that the application is sufficiently complete to...

May 30, 2018

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

AT ASCO Gilead Sciences and Yescarta ® By Acquiring Kite Pharma Gilead Sciences( GILD ) gained Kite’s CAR T technology and its FDA approved therapy Yescarta. At the ASCO 2019 two new analyses were presented from the ZUMA-1 clinical...

June 6, 2019

About Nektar’s product NKTR- 214 at ASCO

The real news coming from the presentation at ASCO related to the combination of Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) was viewed as positive by many analysts and investor until a sell-side negative article led to an unwarranted...

June 4, 2018

Another Approval from Canada for Exelixis Product CABOMETYX®(cabozantinib)

Exelixis and Ipsen Received Approval from Health Canada for CABOMETYX® From Exelixis ( EXEL ) we learned that its partner, Ipsen Biopharmaceuticals Canada , has received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for the treatment of hepatocellular carcinoma (...

November 12, 2019

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024